These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16115768)

  • 1. New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors.
    Hulin B; Cabral S; Lopaze MG; Van Volkenburg MA; Andrews KM; Parker JC
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4770-3. PubMed ID: 16115768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors.
    Caldwell CG; Chen P; He J; Parmee ER; Leiting B; Marsilio F; Patel RA; Wu JK; Eiermann GJ; Petrov A; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1265-8. PubMed ID: 14980678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; McClure LD; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soeller WC; Soglia CB; Treadway JL; VanVolkenburg MA; Wang H; Wilder DC; Olson TV
    J Med Chem; 2006 Jun; 49(11):3068-76. PubMed ID: 16722626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
    Fukushima H; Hiratate A; Takahashi M; Saito M; Munetomo E; Kitano K; Saito H; Takaoka Y; Yamamoto K
    Bioorg Med Chem; 2004 Dec; 12(23):6053-61. PubMed ID: 15519151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
    Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
    Madar DJ; Kopecka H; Pireh D; Yong H; Pei Z; Li X; Wiedeman PE; Djuric SW; Von Geldern TW; Fickes MG; Bhagavatula L; McDermott T; Wittenberger S; Richards SJ; Longenecker KL; Stewart KD; Lubben TH; Ballaron SJ; Stashko MA; Long MA; Wells H; Zinker BA; Mika AK; Beno DW; Kempf-Grote AJ; Polakowski J; Segreti J; Reinhart GA; Fryer RM; Sham HL; Trevillyan JM
    J Med Chem; 2006 Oct; 49(21):6416-20. PubMed ID: 17034148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
    Tran T; Quan C; Edosada CY; Mayeda M; Wiesmann C; Sutherlin D; Wolf BB
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1438-42. PubMed ID: 17174090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
    Drucker DJ
    Diabetes Care; 2007 Jun; 30(6):1335-43. PubMed ID: 17337495
    [No Abstract]   [Full Text] [Related]  

  • 12. Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors.
    Tsai TY; Coumar MS; Hsu T; Hsieh HP; Chien CH; Chen CT; Chang CN; Lo YK; Wu SH; Huang CY; Huang YW; Wang MH; Wu HY; Lee HJ; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3268-72. PubMed ID: 16581245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
    He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
    J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
    Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
    J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.
    Pei Z; Li X; von Geldern TW; Longenecker K; Pireh D; Stewart KD; Backes BJ; Lai C; Lubben TH; Ballaron SJ; Beno DW; Kempf-Grote AJ; Sham HL; Trevillyan JM
    J Med Chem; 2007 Apr; 50(8):1983-7. PubMed ID: 17367123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
    Fukushima H; Hiratate A; Takahashi M; Mikami A; Saito-Hori M; Munetomo E; Kitano K; Chonan S; Saito H; Suzuki A; Takaoka Y; Yamamoto K
    Bioorg Med Chem; 2008 Apr; 16(7):4093-106. PubMed ID: 18243000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; Liu S; McClure LD; McPherson RK; Olson TV; Orena SJ; Parker JC; Rocke BN; Soeller WC; Soglia CB; Treadway JL; Vanvolkenburg MA; Zhao Z; Cox ED
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5638-42. PubMed ID: 17822893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
    Barnett A
    Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.